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Abstract
We previously reported the successful establishment 
of embryonic stem cell (ESC)-like multipotent sperma-
togonial stem cells (mSSCs) from neonatal mouse 
testis. Here, we examined the ability of mSSCs to differ-
entiate into vascular endothelial cells and smooth 
muscle cells, and compared to that of mouse ESCs. We 
used real-time reverse transcriptase polymerase chain 
reaction and immunohistochemistry to examine gene 
expression profiles of mSSCs and ESCs during in vitro 
vascular differentiation. Both mSSCs and ESCs ex-
hibited substantial increase in the expression of meso-
dermal  markers,  such  as  Brachyury,  Flk1,  Mesp1, 
Nkx2.5, and Islet1, and a decrease in the expression of 
pluripotency markers, such as Oct3/4 and Nanog dur-
ing the early stage of differentiation. The mRNA levels 
of vascular endothelial (VE)-cadherin and CD31 gradu-
ally increased in both differentiated mSSCs and ESCs. 
VE-cadherin- or CD31-positive cells formed sprouting 
branch-like structures, as observed during embryonic 
vascular development. At the same time, vascular 
smooth muscle cell-specific markers, such as my-
ocardin and α-smooth muscle actin (SMA), were also 
highly expressed in differentiated mSSCs and ESCs. 
Immunocytochemical analysis revealed that the differ-
entiated cells expressed both α-SMA and SM22-α  pro-
teins, and exhibited the intracellular fibril structure typ-
ical of smooth muscle cells. Overall, our findings 
showed  that  mSSCs  have  similar  vascular  differ-
entiation abilities to those of ESCs, suggesting that 
mSSCs may be an alternative source of autologous 
pluripotent stem cells for vascular regeneration.
Keywords: cell differentiation; endothelial cells; multi-
potent stem cells; myocytes, smooth muscle; sperma-
togonia
Introduction
Constriction or obstruction of blood vessels causes 
restricted blood flow in nearby tissues, leading to 
ischemic vascular diseases, such as stroke, myocardial 
infarction, and peripheral arterial disease. For the 
treatment of ischemic vascular diseases, several 
studies have attempted to generate new blood 
vessel to restore blood circulation and minimize 
tissue damages. 
    In 1997, it was first discovered that endothelial 
progenitor cells (EPCs) circulating in adult peripheral 
bloods could promote vascular regeneration in 
ischemic tissues (Asahara et al., 1997). Since then, 
the therapeutic potential of EPCs has been 
investigated for the treatment of many ischemic 
diseases (Rafii and Lyden, 2003; Shantsila et al., 
2007; Park et al., 2011). However, the limited number 
of EPCs in adult tissues and the lack of in vitro 
expansion methods have made it difficult to obtain 
sufficient EPCs for clinical application. Moreover, 
the EPCs harvested from patients with ischemic 
vascular diseases had a reduced ability to repair 304    Exp. Mol. Med. Vol. 44(4), 303-309, 2012
Figure 1. Experimental scheme of in vitro vascular differentiation proc-
ess and morphological changes of mSSCs and ESCs during 
differentiation. (A) Experimental scheme showing in vitro differentiation 
into vascular cells, (B, C) Representative images of mSSCs (B) and 
ESCs (C) at three different stages. Undifferentiated mSSCs and ESCs 
were cultured on STO in ESC medium (stage 1). Undifferentiated cells 
were aggregated into EBs by using the standard hanging drop method. 
EBs were incubated in vascular differentiation medium containing BMP4, 
VEGF, activin A, and bFGF for 4 days (stage 2). EBs were then attached 
into gelatin-coated plates and cultured until day 14 (stage 3). Scale bar is 
50 μm.
vasculature as compared to those from healthy 
individuals (Hill et al., 2003). As such, autologous 
EPC transplantation into patients with ischemic 
vascular diseases has only marginal therapeutic 
efficacy, as it is the case with transplantation of other 
adult stem cells such as mesenchymal stem cells 
and adipose-derived stem cells. Because of these 
drawbacks, it is important to develop new sources of 
autologous stem cells that highly self-renewal and 
are independent of the host’s disease status.
    Several years ago, autologous multipotent stem 
cells were established from neonatal and adult mice 
testes and were named as multipotent spermatogonial 
stem cells (mSSCs) (Kanatsu-Shinohara et al., 
2004; Guan et al., 2006; Seandel et al., 2007). 
mSSCs exhibited high self-renewal properties and 
express pluripotency - related genes (Oct3/4, Nanog, 
SSEA-1, and alkaline phosphatase), similar to those 
observed in mouse embryonic stem cells (ESCs). 
Recent reports have demonstrated the successful 
establishment of mSSCs from human testes, 
indicating that mSSCs are a new promising source 
of autologous stem cells that do not have the same 
problems as adult stem cells (Conrad et al., 2008; 
Kossack et al., 2009).
    Therefore, the present study aimed to examine 
the ability of mSSCs to differentiate into vascular 
endothelial cells and smooth muscle cells for the 
treatment of ischemic vascular diseases. mSSCs 
used in the present study was previously established 
from SSCs isolated from neonatal mouse testis 
based on the modified Shinohara’s culture method, 
and their ESC-like properties were extensively 
characterized (Kim et al., 2010). 
Results
Mesodermal differentiation of mSSCs 
The mSSCs used in the present study were 
previously characterized to have ESC-like properties 
in cell morphology, expression of pluripotent stem 
cell markers, and DNA methylation profiles (Kim et 
al., 2010). To induce vascular differentiation of 
mSSCs, embryonic bodies (EBs) were generated by 
the hanging drop method and were incubated in 
differentiation media containing vascular endothelial 
growth factor (VEGF), bone morphogenic protein 
(BMP) 4, activin A, and basic fibroblast growth factor 
(bFGF), which are critical modulators of early 
mesodermal differentiation (Pearson et al., 2008). 
During the differentiation process, EBs were grown 
into a uniform size in the suspension culture for 4 
days and were further differentiated by attachment 
to gelatin-coated dishes and cultivation until day 14. 
Throughout the vascular differentiation process, 
cells with a variety of morphologies emerged from EB 
outgrowths (Figure 1). 
    To measure gene expression changes associated 
with early mesodermal differentiation, differentiated 
cells were collected at various time points during in 
vitro differentiation and mRNA levels of pluripotency 
marker genes and mesoderm lineage-related genes 
were analyzed using real-time reverse transcriptase 
polymerase chain reaction (RT-PCR). In both mSSCs 
and ESCs the expression of Oct3/4 and Nanog 
gradually decreased, while the expression of 
Brachyury, early mesodermal marker, dramatically 
increased at day 5 after vascular differentiation 
(Figures 2A and 2B). Other mesodermal markers 
including Flk1 and Mesp1 were maximally expressed 
4 days later (Figure 2B), which was confirmed by 
fluorescence-activated cell sorter (FACS) and 
immunocytochemical analyses (Figures 2C and 
2D). On day 9 and 14 of vascular differentiation, 
significant number of differentiated cells from mSSCs 
and ESCs were positively stained with anti-Flk1 IgG.
    In addition, cardiac transcription factors involved 
in early heart development, Islet1 and Nkx2.5, were 
highly expressed at high levels from days 9 to 14. 
However, at day 9, the expression of these genes 
was weaker in differentiated mSSCs than in 
differentiated ESCs, suggesting that mSSCs have 
less potential for cardiac differentiation than ESCs 
have.Vascular differentiation of spermatogonial stem cells    305
Figure 2. Mesodermal differentiation of mSSCs. (A, B) mRNA profiles of pluripotency-related marker genes (A: Oct3/4, Nanog) and mesoderm lineage - 
specific genes (B: Brachyury, Flk1, Mesp1, Islet1, Nkx2.5) in mSSCs and ESCs during in vitro vascular differentiation process. Gene expression was 
measured using real-time RT-PCR and normalized as its relative ratio to GAPDH. The mRNA levels are expressed relative to the corresponding mRNA 
level at day 0 (undifferentiated mSSCs and ESCs; set as 1). The data were obtained from 3 independent preparations and are expressed as mean ±
SEM. (C, D) Representative FACS histograms and immunofluorescent images showing Flk1 expression in differentiated mSSCs (diff. mSSCs) and differ-
entiated ESCs (diff. ESCs). Approximately 25% and 30% of differentiated cells from mSSCs and ESCs on day 9 of vascular differentiation were positively 
stained with anti-Flk1 IgG. Murine ECs were included as a positive control. Each histogram in (C) is representative of three separate experiments. In addi-
tion, cells on day 14 were stained with anti-Flk1 or nonspecific control IgGs. Scale bar is 50 μm. Nuclei were stained with DAPI. 
Differentiation of mSSCs into vascular endothelial 
cells
To examine whether mSSCs differentiate into vas-
cular endothelial cells (ECs), the expression of vas-
cular endothelial (VE)-cadherin and CD31 was ana-
lyzed using real time RT-PCR. In both mSSCs and 
ESCs, mRNA levels of VE-cadherin continuously in-
creased as differentiation progressed until day 14 
(Figure 3A). CD31 was highly expressed in un-
differentiated ESCs and mSSCs, consistent with a 
previous report demonstrating that pluripotent cells 
in the inner cell mass of mouse blastocysts are 
strongly positive for CD31 (Robson et al., 2001). In 
mSSCs and ESCs, the expression of CD31 dramati-306    Exp. Mol. Med. Vol. 44(4), 303-309, 2012
Figure 3. Vascular endothelial differentiation of mSSCs. (A) mRNA profiles of endothelial specific marker genes, VE-cadherin and CD31, in mSSCs and 
ESCs during in vitro vascular differentiation process. mRNA levels were measured using real-time RT-PCR and normalized as its relative ratio to GAPDH. 
The mRNA levels were expressed relative to the corresponding mRNA level at day 0 (undifferentiated mSSCs and ESCs; set as 1). The data were ob-
tained from 3 independent preparations and are expressed as mean ± SEM. (B, C) Representative images showing the expression of VE-cadherin (B) 
and CD31(C) proteins in differentiated mSSCs (diff. mSSCs) and differentiated ESCs (diff. ESCs). On day 14 of in vitro vascular differentiation, cells were 
immunostained with anti-VE-cadherin, anti-CD31 or nonspecific control IgGs. Murine ECs were included as a positive control. Scale bar is 200 μm. Nuclei 
were stained with DAPI. (D) Representative FACS histograms showing the expression of CD31 in differentiated mSSCs (diff. mSSCs) and differentiated 
ESCs (diff. ESCs). Approximately 7% and 18% of differentiated cells from mSSCs and ESCs on day 14 were positive for CD31. Murine ECs were in-
cluded as a positive control. Each histogram in (D) is a representative of three separate experiments.
cally decreased from the beginning of differentiation 
until day 5 and then continued to increase until the 
end of the vascular differentiation process (Figure 
3A). Immunocytochemical analysis also revealed 
that cells differentiated from mSSCs and ESCs ex-
pressed VE-cadherin or CD31 proteins at their 
cell-cell junctions as observed in ECs, and these 
VE-cadherin- or CD31-positive cells formed sprout-
ed branch-like structures (Figures 3B and 3C). 
When the vascular endothelial differentiation effi-
ciency was assessed using FACS analysis, approx-
imately 7% and 18% of differentiated cells from 
mSSCs and ESCs were positively stained with an-
ti-CD31 IgG, respectively (Figure 3D).
Differentiation of mSSCs into vascular smooth 
muscle cells
To investigate whether mSSCs differentiate into 
vascular smooth muscle cells (VSMCs), expression 
profiles of VSMC-specific markers such as my-
ocardin and α-smooth muscle actin (SMA) were an-
alyzed using real time RT-PCR. In both mSSCs and 
ESCs, mRNA levels of both myocardin and α-SMA 
substantially increased until day 14 (Figure 4A). 
Immunocytochemical analysis in Figure 4B re-
vealed that some differentiated cells from mSSCs 
and ESCs were co-stained with anti-SM22-α and 
anti-α-SMA IgGs, typical markers of adult VSMCs, 
and exhibited the intracellular fibril structure seen in 
the VSMC control (Figure 4B).Vascular differentiation of spermatogonial stem cells    307
Figure 4. Vascular smooth muscle cell differentiation of mSSCs. (A) 
mRNA profiles of VSMC-specific genes, myocardin and α-SMA, in 
mSSCs and ESCs during in vitro vascular differentiation. The mRNA lev-
el was measured using real-time RT-PCR and normalized as its relative 
ratio to GAPDH. The mRNA levels were expressed relative to the corre-
sponding mRNA level at day 0 (undifferentiated mSSCs and ESCs; set 
as 1). The data were obtained from 3 independent preparations and are 
expressed as mean ± SEM. (B) Representative images showing the ex-
pression of SM22α and α-SMA proteins in differentiated cells from 
mSSCs and ESCs. On 14
th day of in vitro vascular differentiation, cells 
were immunostained with anti-SM22α (green), anti-α-SMA (red), or non-
specific control IgGs. VSMCs were included as a positive control. Scale 
bar is 50 μm. Nuclei were stained with DAPI. 
Discussion
Stem cell therapy is a novel and promising ther-
apeutic approach for the treatment of many in-
curable diseases. As such, it has become crucial in 
translational stem cell research to obtain autologous 
stem cells with ESC-like pluripotency and self 
renewal. To that end, many studies have attempted 
to dedifferentiate somatic cells into pluripotent stem 
cells by using somatic nuclear transfer or transcription 
factor-based direct reprogramming methods. However, 
there are many hurdles to overcome before these 
reprogramming methodologies can be clinically used 
to generate patient-specific pluripotent stem cells, 
such as ethical issues and safety concerns asso-
ciated with the use of oocytes and genetic mod-
ification techniques. As an alternative, recent stud-
ies have identified a natural source of pluripotent 
stem cells. Specifically, spermatogonial stem cells 
which normally differentiate into sperm in the testes, 
can be successfully converted to multipotent stem 
cells with ESC-like characteristics, termed mSSCs 
(Kanatsu-Shinohara et al., 2004; Guan et al., 2006; 
Seandel et al., 2007; Conrad et al., 2008; Kossack 
et al., 2009). Therefore, mSSCs may be a source for 
autologous pluripotent stem cells without the prob-
lems associated with ESCs and induced pluripotent 
stem cells (de Rooij and Mizrak, 2008; Skutella, 2009).
    In order to determine whether mSSCs can be 
used as an alternative to ESCs for the treatment of 
ischemic vascular diseases, the present study 
assessed the differentiation potential of mSSCs into 
VSMCs and ECs. During the in vitro differentiation 
process, mSSCs showed a gradual increase in the 
expression of early mesodermal markers, Brachyury, 
Flk1, and Mesp1, and a concomitant decrease in the 
expression of the pluripotency markers, Oct4 and 
Nanog. This differentiation pattern was similar to 
that of ESCs. However, mSSCs were slower than 
ESCs in the expression of transcription factors for 
early cardiac development, Islet1 and Nkx2.5. This 
may reflect a low potential of mSSCs to differentiate 
into the cardiac lineage as compared with ESCs. In 
addition, early cardiac transcription factor such as 
GATA4, ANF and Nkx2.5 expressing adult heart 
side population (SP) cells differentiated into von 
Willebrand factor (vWF)- and CD31-positive 
endothelial cells (Yoon et al., 2007). Further 
differentiation of mSSCs and ESCs into VSMCs and 
ECs was confirmed by the expression of cell 
type-specific genes. The expression levels of 
VE-cadherin and myocardin were slightly reduced 
on day 9 after induction of differentiation; the overall 
expression profile of vascular genes including CD31 
and α-SMA, was similar in both mSSCs and ESCs 
on day 14. This may indicate that mSSCs 
differentiate more slowly at the early vascular 
differentiation stages, but then accelerate to achieve 
similar differentiation pattern as ESCs. In addition, 
immunocytochemistry results showed that cells 
differentiated from both mSSCs and ESCs highly 
expressed endothelial-specific proteins, such as 
VE-cadherin and CD31, at cell-cell junctions and 
formed sprouting branch-like structures. These 
features mimic the embryonic vascular development 
process. Some differentiated cells from mSSCs and 
ESCs expressed both α-SMA and SM22α, and 
exhibited the intracellular fibril structure characteristic 
of VSMC.
    In summary, we demonstrated that mSSCs, like 
ESCs can be efficiently differentiated into VSMCs 
and ECs in vitro. The vascular differentiation 
process of mSSC displayed a developmentally 
appropriate sequence of transcription factor 
expression, similar to ESCs, indicating that mSSCs 
and ESCs have similar self-renewal and differentiation 308    Exp. Mol. Med. Vol. 44(4), 303-309, 2012
properties. Our findings suggest that mSSCs are as 
suitable as ESCs as a source of VSMCs and ECs for 
basic research and potentially therapeutic applications.
Methods
Cell culture
Established mSSCs (CHA_mSSC-1) and murine ESCs 
(D3, ATCC, Manassas, VA) were cultured on mitomycin-C 
(Sigma, Louis, MO) - treated mouse embryonic fibroblasts 
(STO, ATCC) in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco, Carlsbad, CA) supplemented with 20% se-
rum replacement (SR, Gibco), 2-mercaptoethanol (50 μM, 
Gibco), nonessential amino acids (Gibco), penicillin (50 
U/ml, Gibco), streptomycin (50 U/ml, Gibco), and human 
recombinant leukemia inhibitory factor (10
3 U/ml, Millipore, 
Temecular, CA) (Kim et al., 2010). The murine ECs (ATCC) 
and STO were cultured in DMEM containing 10% of fetal 
bovine serum (FBS; Gibco). VSMCs (ScienCell, Carsbad, 
CA) were cultivated in smooth muscle cell culture medium 
(ScienCell).
In vitro vascular differentiation 
Prior to the in vitro differentiation, mSSCs and ESCs were 
cultured on gelatin (Sigma)-coated dishes without feeder 
cells for 2 days. They were then aggregated into EBs using 
standard handing drop method. In brief, mSSCs or ESCs 
(10
3 cells/ml) were suspended in DMEM/F12 medium con-
taining BMP4 (10 ng/ml; Prospecbio, East Brunswick, NJ), 
VEGF (10 ng/ml;, R&D systems Inc., Minneapolis MN), ac-
tivin A (3 ng/ml, Prospecbio), bFGF (5 ng/ml; Prospecbio), 
10% of SR, and 2-mercaptoethanol. 20 μl of cell suspen-
sion was placed on the lids of petri dishes and cultured in 
hanging drops for 2 days. Floating EBs were further cul-
tured in bacteriological petri dishes filled with fresh differ-
entiation medium for another 2 days. EBs were then trans-
ferred to gelatin-coated cell culture dishes filled with basal 
medium supplemented with 2% of FBS, VEGF, bFGF, epi-
dermal growth factor, and insulin growth factor (Lonza, 
Basel, Switzerland) unitl day 14
th.
RT-PCR analysis
Total RNA was extracted from cells using Trizol (Invitrogen, 
Carlsbad, CA) and cDNA was synthesized using the 
Superscript first-strand synthesis system (Invitrogen). 
Real-time PCR was performed with a SYBR green PCR kit 
(Qiagen, Valencia, CA) using a real-time PCR systems 
(Applied Biosystems, Forster city, CA). Specific primer se-
quences are listed in Supplemental Data Table S1. Data 
were analyzed using the ΔΔ Ct method. The raw data were 
normalized to those of the housekeeping gene, glycer-
aldehyde- 3-phosphate dehydrogenase (GAPDH). All re-
actions were performed in triplicate.
Immunocytochemistry
EBs attached to chamber slides were fixed in 4% paraf-
ormaldehyde (Sigma), permeabilized with 0.2% Triton 
X-100 (Sigma), and blocked in 10% normal goat serum 
(Vector Laboratories Inc., Burlingame, CA). Next, EBs 
were incubated with primary IgGs against Flk1 (Cell signal-
ing technology Inc. Danvers, MA), VE-cadherin (BD 
Pharmingen, Bedford, MA), CD31 (BD Pharmingen), SM22α 
(Abcam, Cambridge, MA), α-SMA (Sigma-Aldrich, MO), or 
nonspecific control IgGs. Then, EBs were incubated with 
fluorescence-conjugated secondary IgGs (Chemicon, 
Temecular, CA) and mounted with VectaShield mounting 
medium containing 4, 6-diamidino-2-phenylindole (DAPI). 
Immunofluorescence was analyzed using a fluorescence 
microscope (Carl Zeiss, Oberkochen, Germany). 
FACS analysis 
Cell surface expression of Flk1 and CD31 was analyzed by 
FACS using a FACSAaria flow cytometer (BD Biosciences). 
Cells pretreated with human-FcR blocking reagent (Miltenyi 
Biotec, Bergisch, Galdbach, Germany) were labeled with 
PE-conjugated anti-Flk1 (BD Pharmigen) or anti-CD31 (BD 
Pharmigen) IgGs for 2 h at 4
oC, and then washed with 
ice-cold buffer. Samples were analyzed along with neg-
ative controls stained with appropriate isotype-matched 
nonspecific IgGs.
Statistical analysis
All data were presented as mean ± standard error of the 
mean (SEM).
Supplemental data
Supplemental data include two tables and four figures and 
can be found with this article online at http://e-emm.or.kr/ 
article/article_files/SP-44-4-06.pdf.
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